T cell malignancies after CAR T cell therapy in the DESCAR-T registry
Harvard University · Inserm · +16 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
54
total citations
- FWCI
- 44.48
- Percentile
- 100%
- References
- 29
Citations per year
Authors
13- RDRémy DuléryCorresponding
Harvard University, Inserm, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Antoine, Dana-Farber Cancer Institute, Centre de Recherche Saint-Antoine
- VGVincent Guiraud
Inserm, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Institut Pierre Louis d‘Épidémiologie et de Santé Publique
- SCSylvain Choquet
Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Pitié-Salpêtrière Hospital
- CTCatherine Thiéblemont
Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis
- EBEmmanuel Bachy
Hospices Civils de Lyon
Topics & keywords
Topics
Keywords
- Medicine
- Chimeric antigen receptor
- Lymphoma
- Multiple myeloma
- Oncology
- Malignancy
- Internal medicine
- T cell
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.